Evidence map›Paper›PMID 35715640›Full record

ReviewBritish journal of cancer2022

Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.

Blanca Trujillo, Anjui Wu, Daniel Wetterskog, Gerhardt Attard

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  5. Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Observational
  18. Article
  19. Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Blanca TrujilloUniversity College of London. UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley st, London, WC1E 6BT, UK. b.alba@ucl.ac.uk.ORCID http://orcid.org/0000-0002-5541-9699
Anjui WuUniversity College of London. UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley st, London, WC1E 6BT, UK.ORCID http://orcid.org/0000-0002-1167-7071
Daniel WetterskogUniversity College of London. UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley st, London, WC1E 6BT, UK.ORCID http://orcid.org/0000-0003-4163-6438
Gerhardt AttardUniversity College of London. UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley st, London, WC1E 6BT, UK.ORCID http://orcid.org/0000-0002-4811-7983

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically actionable aberrations across numerous cancer types in real-time. With the development of new therapeutic agents in prostate cancer (PC) including DNA repair targeted therapies, this is especially attractive. However, there is unclarity on how best to screen for PC, improve risk stratification and ultimately how to treat advanced disease. Therefore, there is an urgent need to develop better biomarkers to help guide oncologists' decisions in these settings. Circulating tumour cells (CTCs), exosomes and cell-free DNA/RNA (cfDNA/cfRNA) analysis, including epigenetic features such as methylation, have all shown potential in prognostication, treatment response assessment and detection of emerging mechanisms of resistance. However, there are still challenges to overcome prior to implementing liquid biopsies in routine clinical practice such as preanalytical considerations including blood collection and storage, the cost of CTC isolation and enrichment, low-circulating tumour content as a limitation for genomic analysis and how to better interpret the sequencing data generated. In this review, we describe an overview of the up-to-date clinical opportunities in the management of PC through blood-based liquid biopsies and the next steps for its implementation in personalised treatment guidance.

Indexed as

Cell-Free Nucleic AcidsNeoplastic Cells, CirculatingProstatic NeoplasmsBiomarkers, TumorHumansLiquid BiopsyMaleRNABiomarkers, TumorCell-Free Nucleic AcidsRNA

Identifiers

PMID35715640
PMCPMC9553885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.